Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| docetaxelNCT00127088 | Gustave Roussy, Cancer Campus, Grand ParisPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| Oxaliplatin and irinotecanNCT00180960 | Gustave Roussy, Cancer Campus, Grand ParisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| ErythropoiétineNCT00180999 | Gustave Roussy, Cancer Campus, Grand ParisPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| RituximabNCT00180895 | Gustave Roussy, Cancer Campus, Grand ParisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| GleevecNCT00180830 | Gustave Roussy, Cancer Campus, Grand ParisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| GlivecNCT00180830 | Gustave Roussy, Cancer Campus, Grand ParisPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-11 |
| Gliclazide (Comparison drug)NCT00225342 | University of GlasgowPHASE4 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-08 |
| RosiglitazoneNCT00225342 | University of GlasgowPHASE4 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-08 |
| ABT-089NCT00069849 | AbbottPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-04 |
| Fish oil (Maxepa)NCT00371982 | Assistance Publique - Hôpitaux de ParisNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-09-04 |
| Pegylated Interferon alpha (drug)NCT00196638 | French National Agency for Research on AIDS and Viral HepatitisPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-29 |
| Antiretroviral combination (drugs)NCT00196638 | French National Agency for Research on AIDS and Viral HepatitisPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-29 |
| Pneumo 23NCT00368186 | Wyeth is now a wholly owned subsidiary of PfizerPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-24 |
| Probiotic-containing powderNCT00068094 | National Center for Complementary and Integrative Health (NCCIH)PHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-18 |
| Hydromorphone Hydrochloride Extended-ReleaseNCT00365898 | Purdue Pharma LPPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-08-18 |
| midazolamNCT00030004 | National Center for Complementary and Integrative Health (NCCIH)PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-18 |
| Penicillin test and challengeNCT00363688 | Meir Medical CenterPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-08-15 |
| nebulized epinephrine and nebulized albuterolNCT00361452 | Rambam Health Care CampusPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-08-08 |
| Divalproex Sodium (Depakote® Sprinkle Capsules)NCT00067431 | AbbottPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-08-04 |
| OlanzapineNCT00071253 | AbbottPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-08-04 |
| Divalproex Sodium (Extended-Release Tablets)NCT00071253 | AbbottPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-08-04 |
| Divalproex Sodium (Delayed-Release Tablets)NCT00071253 | AbbottPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-08-04 |
| Tilarginine Acetate Injection intravenous infusionNCT00112281 | Arginox PharmaceuticalsPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2006-08-04 |
| CalcijexNCT00062699 | AbbottPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2006-08-02 |
| Zemplar (paricalcitol injection)NCT00062699 | AbbottPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2006-08-02 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |